The clinical trials that established Igalmi’s effectiveness were run on patients who had been admitted to a hospital or a research unit and who stayed under medical supervision for at least 24 hours after their dose. That sentence is in the label, in the section headed Clinical Studies, and it is still there in the version FDA approved on November 13.

What changed on November 13 is that the same drug can now be taken at home by a patient nobody is watching.

Teva Pharmaceuticals announced the approval on November 16, three days after the action date recorded in FDA’s own database. It is the first treatment FDA has approved for a patient to self-administer during an acute agitation episode in schizophrenia, schizoaffective disorder, or bipolar I or II disorder. The same approval is also the event named as the condition on up to $67.5 million that Teva may owe to what is left of the company that developed the drug.

Those two things are not connected by anyone’s intent, so far as the record shows. They are connected by a contract.

Three changes, not one

Comparing the approved label against the version it replaces shows FDA changed three things at once. Teva’s announcement describes one of them.

The first is the setting. The previous label, revised in November 2025, said plainly: “IGALMI should be administered under the supervision of a healthcare provider. A healthcare provider should monitor vital signs and alertness after IGALMI administration to prevent falls and syncope.” The word unsupervised does not appear anywhere in that document. The new label splits dosing into two sections, one headed Recommended Dosage in the Healthcare Supervised Setting and one headed Recommended Dosage in the Unsupervised Setting.

The second is the indication. The old label covered “agitation associated with schizophrenia or bipolar I or II disorder.” The new one covers “agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.” Schizoaffective disorder is new. Teva’s announcement states the full new indication without noting that part of it was added.

The third is duration. The old label carried a limitation that the safety and effectiveness of Igalmi “have not been established beyond 24 hours from the first dose.” That sentence is gone. In its place: Igalmi “is not indicated for preventive treatment of agitation or for the underlying psychiatric disorder,” and “the safety and effectiveness of chronic, daily use of IGALMI have not been studied.” The ceiling moved from a day to an undefined period short of daily use.

The home regime is the narrow one

The phrase at-home approval suggests the supervised constraints were lifted. The label does close to the opposite. Almost every parameter is tighter outside the clinic than inside it.

Under supervision, an adult can receive 120 micrograms for mild or moderate agitation or 180 for severe, then up to two more doses at least two hours apart, to a maximum of 240 or 360 micrograms in a day. A healthcare professional may cut the film in half with scissors to produce a 60 or 90 microgram dose.

At home, the dose is 120 micrograms. If agitation recurs, one more 120 microgram dose may be taken, and only “after at least 12 hours have passed since the previous dose.” The label states it twice: “Do not administer more than one dose within a 12-hour period.” The two-hour repeat window does not exist outside the clinic.

The products are physically different. The supervised film is 120 or 180 micrograms, blue, with two darker blue spots. The unsupervised film is 120 micrograms only, imprinted “D12” in black. Patients taking it at home are told: “Do not split, cut, chew, or swallow the film.” The dose-reduction steps that exist under supervision are unavailable, because the film that permits them is not the film dispensed for home use.

And two groups are excluded outright. The label reads: “Use of IGALMI in the unsupervised setting is not recommended in the following patients: geriatric patients (65 years of age and older); patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B), or severe (Child-Pugh Class C) hepatic impairment.” Anyone over 64, and anyone with liver impairment of any grade, is outside the at-home regime. Under supervision, both groups have their own dosing rows.

What the label asks for, and does not say who does

Section 2.1 of the label is headed Important Recommendations Prior to and During Treatment. It sits above both the supervised and unsupervised dosing sections, and it applies to both. It survived this approval unchanged in substance.

Before treatment, it instructs: “Assess heart rate and blood pressure, including orthostatic measurements.” Also assess for a history of hypotension, orthostatic hypotension, advanced heart block, severe ventricular dysfunction or syncope, and assess the risk of orthostatic hypotension, syncope and falls. During treatment: “Monitor for hypotension and orthostatic hypotension. Monitor for presyncope, syncope, and falls.”

Those instructions are there because of what the drug does. Section 5.1 is unchanged: “IGALMI causes dose-dependent hypotension, orthostatic hypotension, and bradycardia.” In the two supervised trials, orthostatic hypotension was recorded in 18 percent of patients at 180 micrograms and 16 percent at 120 micrograms, against 9 percent on placebo. Somnolence ran at 23 and 22 percent against 6 percent on placebo, and patients are told not to drive or operate machinery for at least eight hours after a dose.

An orthostatic blood pressure measurement means taking blood pressure lying or sitting, then standing, and comparing them. The label does not say who performs that measurement, or the subsequent monitoring, in a home where no healthcare provider is present. It does not require a caregiver, name one, or describe a role for one. It does not specify equipment.

There is no Risk Evaluation and Mitigation Strategy. The phrase appears nowhere in the approved label. That is not the same as an absence of risk controls: the controls FDA chose are in the labeling itself, in the single fixed dose, the 12-hour interval, the uncuttable film, and the exclusion of older patients and those with hepatic impairment. But it does mean there is no program outside the label governing who may prescribe it, who may dispense it, or what has to happen before a patient takes one at home.

Where the effectiveness evidence comes from

The clinical case for the setting change and the clinical case for the drug are two different things, and the label keeps them apart more clearly than the announcement does.

Section 14, Clinical Studies, is the part of a label that carries effectiveness. It reads: “The effectiveness of IGALMI for the acute treatment of agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults was established in two randomized, double-blind, placebo-controlled, fixed-dose studies (Studies 1 and 2).” Those are the SERENITY trials, 380 and 378 patients, with the primary endpoint the change in the Positive and Negative Syndrome Scale-Excited Component at two hours. At 180 micrograms the placebo-adjusted difference was 5.5 points in one study and 5.4 in the other.

And, in the same section: “In both studies, patients were admitted to a clinical research unit or a hospital and remained under medical supervision for at least 24 hours following treatment.”

The at-home trial does not appear in Section 14 at all. It appears in Section 6, Adverse Reactions, under the heading Study in the Unsupervised Setting: “The safety of IGALMI 120 mcg was evaluated in 208 adult patients… in one randomized, 12-week, outpatient, placebo-controlled study (Study 3). Of these patients, 102 received IGALMI and 106 received placebo.”

That placement is the regulatory answer to what the at-home study was for. Teva’s announcement says the trial “met its primary endpoint of safety and tolerability,” which is accurate, and FDA filed it where safety findings go. Somnolence in that study ran at 55 percent against 42 percent on placebo, higher in both arms than in the supervised trials. The efficacy argument for taking this drug still rests on people who were in a hospital.

The approval landed inside a bankruptcy

Igalmi was developed by BioXcel Therapeutics, which submitted the at-home application on January 14, 2026 and did not survive to see it approved.

BioXcel filed for Chapter 11 on August 27, 2026, in the District of Delaware, case number 26-11360. Nasdaq suspended its stock on September 8; it trades over the counter as BTAIQ. Teva served as the stalking horse bidder in the court-supervised sale, which closed on October 26 and which Teva announced on October 27.

The terms are in BioXcel’s own filing. Teva paid “upfront cash consideration of $57.5 million,” with a $5.75 million deposit credited against it, plus certain cure costs, and acquired Igalmi and BXCL501. Two other programs stayed with the debtors.

Then the contingent half. The estate “may receive a development milestone payment of up to $67.5 million” tied to FDA approval of the at-home supplemental application. And if that approval had not been obtained by February 28, 2027, the structure provided instead for commercial milestone payments of up to $20.0 million in total. Teva’s own quarterly filing describes the same arrangement from the other side, as “time-based payments linked to the timing of the pending FDA approval of BXCL-501, including potential delays in approval.”

The November 13 approval meets the stated approval condition attached to that contingent consideration. Nothing in the public record establishes that any payment has been made or has become due, and neither company has said so. As of November 19, BioXcel has filed nothing with the SEC since October 30.

What the approval does establish is that the ceiling on the contingent consideration is $67.5 million rather than the $20.0 million alternative, more than three times as large, and above the $57.5 million Teva paid up front. Any proceeds would go to a company that has announced its wind-down and will not keep developing the drug. BioXcel’s board terminated its chief executive, chief financial, chief scientific and chief legal officers effective October 31, and the company is renaming itself BX Liquidation, Inc. ahead of what its filing calls a “planned wind-down and liquidation.”

What is not known

Teva has not said when it will commercialize the at-home indication, saying only that it will announce plans “at a later date,” and has not said publicly whether pricing will differ from the supervised product. It has not publicly described what patient training, monitoring equipment or caregiver guidance will accompany a product whose label calls for orthostatic measurement in a setting with no clinician in it.

FDA’s Drugs@FDA database now lists Teva as the applicant for the application, so the approval was recorded under the buyer rather than the bankrupt developer. The approval settles the label and meets one contractual condition. It does not settle who takes a patient’s standing blood pressure at home, or whether any milestone payment has been made.